In a Phase II study in patients with advanced DLBCL, G demonstrated promising activity and an acceptable safety profile when combined with CHOP (G-CHOP) as a first-line treatment [9]. The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.